MRKR
NASDAQMarker Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.34-0.03 (-1.82%)
01:45 PM07:45 PM
News · 26 weeks11-100%
2025-12-212026-06-14
Mix290d
- SEC Filings2(100%)
Latest news
25 items- SECSEC Form 10-Q filed by Marker Therapeutics Inc.10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECMarker Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECSEC Form DEFA14A filed by Marker Therapeutics Inc.DEFA14A - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECSEC Form DEF 14A filed by Marker Therapeutics Inc.DEF 14A - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECSEC Form 10-K filed by Marker Therapeutics Inc.10-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- PRMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsPhase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a
- SECSEC Form PRE 14A filed by Marker Therapeutics Inc.PRE 14A - Marker Therapeutics, Inc. (0001094038) (Filer)
- PRMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceHOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event:Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Wednesday, February 25, 2026Time: 8:00 – 8:30 a.m. ESTTrack: Track 3Webcast Link: "Events and Presentations" section on Marker's IR
- SECMarker Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Financial Statements and Exhibits8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- PRGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell TechnologyHOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors, today announced that Baylor College of Medicine's TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026. The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in pa
- PRBaylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic CancerClinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tu
- INSIDERSEC Form 4 filed by Director Knobil Katharine4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- INSIDERSEC Form 4 filed by Director Eansor Norman David4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- INSIDERSEC Form 4 filed by Director Elms Steve4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- SECMarker Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECSEC Form 10-Q filed by Marker Therapeutics Inc.10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)
- SECMarker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- PRMarker Therapeutics appoints Kathryn Penkus Corzo to Board of DirectorsHOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in
- INSIDERSEC Form 4 filed by Director Corzo Kathryn Penkus4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Vera Juan4 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- INSIDERSEC Form 3 filed by new insider Corzo Kathryn Penkus3 - Marker Therapeutics, Inc. (0001094038) (Issuer)
- PRMarker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual MeetingOngoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that data from the Phase 1 APOLLO study will be presented in two posters at the 67th American Society of
- SECMarker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Marker Therapeutics, Inc. (0001094038) (Filer)
- PRMarker Therapeutics Announces First Patient Treated in Off-the-Shelf ProgramMarker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the first patient has been treated in the Company's OTS program, with encouraging preliminary safety data. Marker is evaluating the safety and effi
- PRMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceHOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025 in New York. Fireside Chat Details: Event:H.C. Wainwright 27th Annual Global Investment ConferenceDate: Wednesday, September 10, 2025Time: 12:30 – 1:00 p.m. EDTLocation: Lotte New York Palace Hotel, New York City, NYWebcas
MRKR FAQ
6 questionsWhat does Marker Therapeutics Inc. do?
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid...Where does MRKR stock trade?
Marker Therapeutics Inc. (MRKR) is listed on NASDAQ.What sector and industry is MRKR in?
Marker Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MRKR?
Marker Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy with a $800.00 price target on 2025-03-05.What companies are similar to MRKR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MRKR side-by-side with any of them on Quantisnow.How can I track MRKR on Quantisnow?
Quantisnow aggregates Marker Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRKR to receive live email and push alerts on every new disclosure.